# A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

> **NCT01067521** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 1404 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer acetate (GA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01067521
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-22
- **Primary completion:** 2012-05-08
- **Final completion:** 2017-05-12
- **Target enrollment:** 1404 (ACTUAL)
- **Last updated:** 2021-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067521, "A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01067521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*